

Resource Summary Report

Generated by [NIF](#) on Aug 1, 2026

BV421 Mouse Anti-Human CD137 (4-1BB)

RRID:AB_2722503

Type: Antibody

Proper Citation

BD Biosciences Cat# 564091, RRID:AB_2722503

Antibody Information

URL: http://antibodyregistry.org/AB_2722503

Proper Citation: BD Biosciences Cat# 564091, RRID:AB_2722503

Target Antigen: CD137 (4-1BB)

Host Organism: mouse

Clonality: monoclonal

Comments: Applications: Flow cytometry

Antibody Name: BV421 Mouse Anti-Human CD137 (4-1BB)

Description: This monoclonal targets CD137 (4-1BB)

Target Organism: human

Clone ID: 4B4-1

Antibody ID: AB_2722503

Vendor: BD Biosciences

Catalog Number: 564091

Record Creation Time: 20250819T235525+0000

Record Last Update: 20250820T065018+0000

Ratings and Alerts

No rating or validation information has been found for BV421 Mouse Anti-Human CD137 (4-1BB).

No alerts have been found for BV421 Mouse Anti-Human CD137 (4-1BB).

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 6 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Shi Y, et al. (2025) pT² enhances mRNA translation and potentiates CAR T cells for solid tumor eradication. *Cell*.

Jayaraman S, et al. (2023) Barcoding intracellular reverse transcription enables high-throughput phenotype-coupled T cell receptor analyses. *Cell reports methods*, 3(10), 100600.

Santegoets SJ, et al. (2023) The combined HPV16-E2/E6/E7 T cell response in oropharyngeal cancer predicts superior survival. *Cell reports. Medicine*, 4(11), 101262.

Martin AL, et al. (2023) Anti-4-1BB immunotherapy enhances systemic immune effects of radiotherapy to induce B and T cell-dependent anti-tumor immune activation and improve tumor control at unirradiated sites. *Cancer immunology, immunotherapy : CII*, 72(6), 1445.

Garcia-Valtanen P, et al. (2022) SARS-CoV-2 Omicron variant escapes neutralizing antibodies and T cell responses more efficiently than other variants in mild COVID-19 convalescents. *Cell reports. Medicine*, 3(6), 100651.

Singh S, et al. (2020) Neutralizing Antibodies Protect against Oral Transmission of Lymphocryptovirus. *Cell reports. Medicine*, 1(3).